Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Express Scripts
Harvard Business School
Baxter
Medtronic

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

CLARITIN-D 24 HOUR Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Claritin-d 24 Hour patents expire, and what generic alternatives are available?

Claritin-d 24 Hour is a drug marketed by Bayer Healthcare Llc and is included in one NDA.

The generic ingredient in CLARITIN-D 24 HOUR is loratadine; pseudoephedrine sulfate. There are thirty-nine drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the loratadine; pseudoephedrine sulfate profile page.

Drug patent expirations by year for CLARITIN-D 24 HOUR
Recent Clinical Trials for CLARITIN-D 24 HOUR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of MichiganPhase 2
BayerPhase 4
EMSPhase 3

See all CLARITIN-D 24 HOUR clinical trials

Recent Litigation for CLARITIN-D 24 HOUR

Identify potential future generic entrants

District Court Litigation
Case NameDate
MERCK SHARP & DOHME CORP. v. ACTAVIS LABORATORIES FL, INC.2015-08-06
Simonian v. Merck & Co., Inc.2010-02-25
SCHERING CORPORATION v. SANDOZ INC.2008-04-03

See all CLARITIN-D 24 HOUR litigation

Paragraph IV (Patent) Challenges for CLARITIN-D 24 HOUR
Tradename Dosage Ingredient NDA Submissiondate
CLARITIN-D 24 HOUR TABLET, EXTENDED RELEASE;ORAL loratadine; pseudoephedrine sulfate 020470

US Patents and Regulatory Information for CLARITIN-D 24 HOUR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc CLARITIN-D 24 HOUR loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 020470-002 Nov 27, 2002 OTC Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CLARITIN-D 24 HOUR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Healthcare Llc CLARITIN-D 24 HOUR loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 020470-002 Nov 27, 2002   Start Trial   Start Trial
Bayer Healthcare Llc CLARITIN-D 24 HOUR loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 020470-002 Nov 27, 2002   Start Trial   Start Trial
Bayer Healthcare Llc CLARITIN-D 24 HOUR loratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 020470-002 Nov 27, 2002   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Colorcon
Express Scripts
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.